Anavex Life Sciences Corp.AVXLNASDAQ
Loading
EV/EBITDA Over TimeContracting
Percentile Rank14
Studio
Year-over-Year Change

Enterprise value to EBITDA ratio

Latest
-14.16
↓ 33% vs avg
Percentile
P14
Within normal range
Streak
1 yr
Consecutive declineContracting
Average
-10.68
Historical baseline
PeriodValueYoY Change
2025-14.16-78.0%
2024-7.95+0.4%
2023-7.98+41.0%
2022-13.54+53.7%
2021-29.25-285.7%
2020-7.58-65.5%
2019-4.58+5.0%
2018-4.82+47.0%
2017-9.10-15.6%
2016-7.87-